OncoMatch/Clinical Trials/NCT06099093

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Is NCT06099093 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies 18F-DCFPyl for prostate cancer.

Phase 4RecruitingBrigham and Women's HospitalNCT06099093Data as of May 2026

Treatment: 18F-DCFPyl — The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer).

Check if I qualify

Extracted eligibility criteria

Cancer type

Prostate Cancer

Biomarker criteria

Required: FOLH1 PSMA-avid lesion on PET

≥1 PSMA-avid lesion on 68Ga-PSMA-11 PSMA-PET performed within 120 days of study entry

Disease stage

Metastatic disease required

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Dana Farber Cancer Institute · Boston, Massachusetts
Brigham and Womens Hospital · Boston, Massachusetts

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify